Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of Hengpagliflozin in different subtypes of type 2 diabetes
ChiCTR2500115195Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM) and atherosclerotic disease, sponsored by Beijing Hospital. Primary endpoints: HbA1c target achievement rate and Blood uric acid. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2500115195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115195.